Literature DB >> 20713771

Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression.

Sara Samimi1, Bernice Benoit, Katherine Evans, E John Wherry, Louise Showe, Maria Wysocka, Alain H Rook.   

Abstract

OBJECTIVES: To investigate the expression profile of programmed death-1 (PD-1) on T cells derived from patients with cutaneous T-cell lymphoma (CTCL), analyze a potential mechanism responsible for upregulation of PD-1, and assess the correlation between blockade of its signaling pathway and improvement in immunological function.
DESIGN: Translation research study.
SETTING: University medical center. PARTICIPANTS: Patients with Sézary syndrome, patients with mycosis fungoides, and healthy volunteers. MAIN OUTCOME MEASURES: Programmed death-1 expression on T cells by flow cytometry and interferon γ (IFN-γ) production by enzyme-linked immunosorbent assay.
RESULTS: We report significantly increased PD-1 expression on CD4(+) T cells from patients with Sézary syndrome compared with CD4(+) T cells from patients with mycosis fungoides and healthy volunteers. Both CD26(-) and CD26(+) populations of CD4(+) T cells demonstrated increased expression of PD-1, which was upregulated by the engagement of the T-cell receptor with anti-CD3/CD28 antibodies. In addition, blockade of the signaling pathway with blocking antibodies to PD-1 or its ligand PD-L1 led to an increase in the capacity to produce IFN-γ among some patients. Finally, longitudinal studies of 1 patient revealed a progressive decrease in PD-1 expression on CD4(+) T cells with improvement of clinical disease.
CONCLUSION: Our data imply that increased PD-1 expression in Sézary syndrome may play a role in attenuating the immune response and provide further insight into the immunosuppressive nature of CD4(+) T cells in Sézary syndrome and suggest another potential means of targeted therapy for these patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713771      PMCID: PMC4467572          DOI: 10.1001/archdermatol.2010.200

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  34 in total

1.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

2.  Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain).

Authors:  R Dummer; P W Heald; F O Nestle; E Ludwig; E Laine; S Hemmi; G Burg
Journal:  Blood       Date:  1996-08-15       Impact factor: 22.113

3.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

4.  The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens.

Authors:  C L Berger; N Wang; I Christensen; J Longley; P Heald; R L Edelson
Journal:  J Invest Dermatol       Date:  1996-09       Impact factor: 8.551

Review 5.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

6.  Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Authors:  Christian Blank; Juergen Kuball; Simon Voelkl; Heinz Wiendl; Bernd Becker; Bernhard Walter; Otto Majdic; Thomas F Gajewski; Mathias Theobald; Reinhard Andreesen; Andreas Mackensen
Journal:  Int J Cancer       Date:  2006-07-15       Impact factor: 7.396

7.  RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma.

Authors:  Jens M Chemnitz; Daniela Eggle; Julia Driesen; Sabine Classen; James L Riley; Svenja Debey-Pascher; Marc Beyer; Alexey Popov; Thomas Zander; Joachim L Schultze
Journal:  Blood       Date:  2007-07-20       Impact factor: 22.113

8.  Infections complicating mycosis fungoides and Sézary syndrome.

Authors:  P I Axelrod; B Lorber; E C Vonderheid
Journal:  JAMA       Date:  1992-03-11       Impact factor: 56.272

9.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

View more
  46 in total

Review 1.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 2.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

3.  Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression.

Authors:  Nicholas Borcherding; Andrew P Voigt; Vincent Liu; Brian K Link; Weizhou Zhang; Ali Jabbari
Journal:  Clin Cancer Res       Date:  2019-02-04       Impact factor: 12.531

4.  Single-cell mass cytometry analysis of human tonsil T cell remodeling by varicella zoster virus.

Authors:  Nandini Sen; Gourab Mukherjee; Adrish Sen; Sean C Bendall; Phillip Sung; Garry P Nolan; Ann M Arvin
Journal:  Cell Rep       Date:  2014-07-17       Impact factor: 9.423

5.  Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Authors:  Michael S Khodadoust; Alain H Rook; Pierluigi Porcu; Francine Foss; Alison J Moskowitz; Andrei Shustov; Satish Shanbhag; Lubomir Sokol; Steven P Fling; Nirasha Ramchurren; Robert Pierce; Asa Davis; Richard Shine; Shufeng Li; Sophia Fong; Jinah Kim; Yi Yang; Wendy M Blumenschein; Jennifer H Yearley; Biswajit Das; Rajesh Patidar; Vivekananda Datta; Erin Cantu; Justine N McCutcheon; Chris Karlovich; P Mickey Williams; Priyanka B Subrahmanyam; Holden T Maecker; Steven M Horwitz; Elad Sharon; Holbrook E Kohrt; Martin A Cheever; Youn H Kim
Journal:  J Clin Oncol       Date:  2019-09-18       Impact factor: 44.544

Review 6.  The biomarker landscape in mycosis fungoides and Sézary syndrome.

Authors:  Brittany Dulmage; Larisa Geskin; Joan Guitart; Oleg E Akilov
Journal:  Exp Dermatol       Date:  2017-02-02       Impact factor: 3.960

Review 7.  Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.

Authors:  Louise Photiou; Carrie van der Weyden; Christopher McCormack; H Miles Prince
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

8.  Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1.

Authors:  Sharrón L Manuel; Mohit Sehgal; John Connolly; George Makedonas; Zafar K Khan; Jay Gardner; Michael R Betts; Pooja Jain
Journal:  J Clin Immunol       Date:  2013-07-26       Impact factor: 8.317

9.  Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.

Authors:  Carolyn S Lee; Alexander Ungewickell; Aparna Bhaduri; Kun Qu; Dan E Webster; Randall Armstrong; Wen-Kai Weng; Cody J Aros; Angela Mah; Richard O Chen; Meihong Lin; Uma Sundram; Howard Y Chang; Markus Kretz; Youn H Kim; Paul A Khavari
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

10.  Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.

Authors:  Jin-Sung Chung; Lisa H Shiue; Madeleine Duvic; Amit Pandya; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Blood       Date:  2011-01-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.